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Summary.-The oestrogen receptor (RE) status of the primary tumour has been
assessed in 466 of a consecutive series of 550 patients with primary operable breast
cancer.
All patients were followed up (without treatment) until the development of recur-
rence or metastases. Distant metastases have so far occurred in 124 patients and 82
have had symptomatic local or regional recurrence.
A significant correlation exists between the RE status of the primary tumour and
subsequent patterns of metastasis.
Symptomatic metastases to regional lymph nodes are more common with RE-
cancers. There is no significant difference in either time of onset or total incidence of
distant metastases between patients with RE+ and RE- tumours. Distribution of
distant metastases is inflenced by RE status: RE+ tumours tend to recur in bone,
RE- tumours show affinity for viscera.
IN PATIENTS with advanced breast
cancer, the anatomic site of distant meta-
stases is an important clinical factor which
relates both to response to endocrine
therapy (Baum, 1980) and survival (Shim-
kim et al., 1954; Papaioannou et al., 1967;
Cutler et al., 1969). Patients with skeletal
metastases have a higher response rate to
endocrine therapy (Taylor, 1962) and a
more favourable overall prognosis (Shim-
kin et al., 1954; Papaioannou et al., 1967;
Cutler et al., 1969) than those with visceral
secondaries.
Factors influencing the distribution of
distant metastases in breast cancer remain
unclear.
The oestrogen receptor (RE) status of
human breast cancer has also been shown
to relate to response to endocrine therapy
(McGuire et al., 1975; Roberts et al., 1978)
andsurvival (Bishop etal., 1979).
This study is a search for any relation-
ship between RE status of the primary
breast tumour and subsequent incidence
and distribution of secondary metastases.
PATIENTS AND METHODS
The Nottingham/Tenovus series of 550
female patients aged 28-75 years with
primary operable breast cancer presented to
one surgeon (R.W.B.) between 1973 and 1979.
In all cases, tumours were judged clinically
to be less than 5 cm in diameter, and patients
with distant metastases at the time of pre-
sentation were excluded from the study.
A simple or subcutaneous mastectomy was
carried out in all cases. The Nottingham
staging procedure has been previously de-
scribed (Maynard et al., 1978) but briefly one
lymph node is taken, at the time of mast-
ectomy, each from the lower axilla, the apex
ofthe axilla and the second intercostal space.
Patients were categorized as Stage A if all
nodes are histologically tumour-free, Stage B
for low axillary involvement and Stage C for
involvement of either apical axillary or
internal mammary nodes. All patients areRE STATUS AND SITES OF M1ETASTASIS IN BREAST CANCER
followed up at 3-monthly intervals to 18
months, and at 6-monthly intervals there-
after. No patient receives any treatment
before the development of recurrence.
For the purpose of this study, categories of
recurrence are defined thus:
"Spot" recurrence: A small discrete skin
metastases which is confirmed histologically.
Local recurrence: Multiple, symptomatic or
progressive metastases in mastectomy flaps
which are confirmed histologically.
Regional recurrence: Symptomatic meta-
stases in axillary or supraclavicular nodes,
which are confirmed histologically.
Distant recurrence: Any distant meta-
stases, confirmed by clinical examination,
abnormal liver-function tests, appropriate
X-rays, liver or brain scans or biopsy.
Asymptomatic but palpable axillary nodes
are not regarded as recurrences unless histo-
logical proofis available.
Oestradiol receptor ass8ay.-Oestradiol-re-
ceptor status ofthe primary breast cancer has
so far been evaluated in 466 patients.
Receptor data were not obtained in 84
patients, either because all the tumour at
mastectomy was used for frozen section or
paraffin histology or because specimens were
lost. Tumour samples taken at mastectomy
were frozen and stored in liquid N2 before
being transported on dry ice to the Tenovus
Institute, Cardiff, where the assay is per-
formed by the dextran-coated-charcoal
method (Maynard et al., 1979).
Tumours are considered to be RE+ when
they contain > 5 fmol specific oestradiol
binding per mg cytosol protein.
Seven patients, 4 of whom had co-existent
primary tumours of another organ, 2 who
were referred elsewhere for follow-up, and one
with 2 simultaneous tumours of different RE
status, are excluded from the analysis, leaving
459 evaluable patients.
RESULTS
Ofthe 459 evaluable patients, 264 (58%)
have RE+ primary breast cancers.
Local recurrence: major local recurrence
has so far appeared in 33 patients, while
a further 44 have developed single "spot"
recurrence in mastectomy flaps. RE status
is not significantly related to either major
local recurrence (Table I) or to the total
of major local and "spot" skin metastases
(Table II).
TABLE I. Oestrogen-receptor status and
local recurrence
RE status
+ -
Local recurrence 15
No recurrence 249
Total 264
18
177
195
x2=1-6; 1 d.f.; P=0-2.
TABLE II.-RE status and total skin
recurrence
RE status
+ -
Skin recurrence
No recurrence
Total
47
217
264
30
16G
195
x2=0-31; 1 d.f.; P>0-5.
Regional recurrence: 49 patients have
developed symptomatic recurrence in
axillary or supraclavicular nodes. The
incidence of this complication is signifi-
cantly greater in patients with RE-
cancers (Table III).
TABLE III. RE status and regional
recuarrence
RE status
Recurrence
No recurrence
Total
20
244
264
29
166
195
X2=5-52; 1 (I.f.; 0-025>P>0-01.
Distant recurrence: distant metastases
have so far appeared in 124 patients.
RE status is related to neither time of
onset of distant metastases after mast-
ectomy (Fig. 1) nor to the total incidence
of distant metastases (Table IV). The RE
status is, however, related to the anatomic
site of distant metastases: RE+ tumours
tend to metastasize initially to skeleton,
whilst RE- cancers show affinity for initial
distant spread to viscera (lung, liver,
intra-abdominal organs and central ner-
vous system) (Table IV). Survival of
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FIG. 1.-Time of occurrence of distant
metastases. RE+ (n= 264) vS RE- (n= 195).
Median duration of follow-up after mast-
ectomy = 30 months. P > 0 05 by method of
Mantel (1966).
TABLE IV.-RE status and distant meta-
stasis
RE status
(a) No metastases 195
Total distant
metastases 69
(b) Site ofinitial
distant metastases
Bone 42
Viscera 17
Combined 10
140 X2 =(
55
13
36
6
P<
patients in whom the first dista
stases appear in bone is sigi
longer than that of patients whc
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FIG. 2.-Survival after recurrence in pi
with distant metastases. Initial bone
stases (n = 55) vs initial visceral s
aries (n=53). Median duration offoll
after onset of distant metasta
months. P < 0 001 by method of ]
(1966).
distant recurrence develop in viscera
(Fig. 2).
The disease stage, as assessed by the
degree of lymph-node involvement at the
time ofmastectomy, which may be related
to the total incidence of regional and
distant metastases, is not significantly
related to RE status (Table V).
TABLE V.-Oestrogen receptor status and
disease stage at mastectomy
RE status
Stage*
A
B
C
Total
+
134
82
48
264
116
46
33
195
x2=3-9; 2 d.f.; 0-20>P> 0-10, N.S.
* For method of staging see text.
DISCUSSION
0 15; 1 d.f.; RE status of breast cancer is an impor-
tant prognostic factor which is related to
N.S. both tumour-free interval (Maynard et al.,
1978) and survival (Bishop et al., 1979).
21-8; 2 d.f. Patients with RE- cancers fare worse on
<°00005 both these counts than those whose
tumours are RE+. This studydemonstrates
~nt meta- that patients with RE- primary tumours
nrificantly are more likely to develop symptomatic
)s i a . recurrence in regional lymph nodes than
are those with RE+ primaries (Table III)
despite a similar incidence of involved
lymph nodes in both groups ofpatients at
mastectomy (Table V). RE- breast can-
cers tend to be poorly differentiated
(Elston et al., 1980) and have a rapid rate
of cellular replication (Meyer et al., 1977),
Bone and it is possible that these differences of
clinical expression as regards tumour-free
interval, survival and symptomatic nodal
recurrence between RE+and RE-tumours
VisceraI may be related to a more rapid growth of
12 15 the latter.
The results of this study also demon-
atients strate a significant relationship between
meta-
iecond- the RE status of the primary breast
low-up cancer and sites of distant metastases:
ses = 7 RE+ cancers tend to metastasize to bone
MIantel while RE- tumours are more likely to
]OD
a) a) 90
a)
co 30
4) 2
co 7
-L -L -L 1 6 12 is 24 31 11 1.
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recur in viscera. These findings are in
agreement with those of Walt et al. (1976)
and Stewart et al. (1981) but contrary to
those of Hahnel et al. (1979) in whose
series sites of secondary metastases were
unrelated to RE status.
Mechanisms governing the distribution
of metastases in breast cancer to different
sites are unclear. This study demonstrates
that RE+ breast cancers favour the bony
skeleton as a site of recurrence. It is con-
ceivable that oestrogenic hormones, acting
via receptors on the RE+ cancer cells,
could play some part in governing the
preferential growth of metastases at this
site. Possibly the hormone-cell interaction
could, by some unknown pathway, alter
the environment in bone (metabolic or
otherwise) to favour growth of these
cancer cells. RE- cancer cells, however,
would not be subject to these hormonal
influences but, having a more rapid rate of
proliferation (Meyer et al., 1977) and pos-
sibly being more virulent, would grow at
whichever site that they happened to
come to rest. Exact mechanisms, however,
remain uncertain.
Other authorities have reported pre-
viously that patients with predominantly
bony secondaries survive significantly
longer after recurrence than those with
visceral metastases (Cutler et al., 1969)
and ourfindings agree with that conclusion
(Fig. 2). While survival will obviously be
influenced by treatment, no attempt has
been made to take this factor into account
in this study. It is clear that the longer
survival of patients with RE+ cancers
(Bishop et al., 1979) is related not only to a
greater likelihood ofresponse to endocrine
therapy (McGuire et al., 1975) but also to
their less rapid natural growth rate;
it may also be that the distribution of
their metastases to less lethal secondary
sites plays some part.
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